March 29, 2025 - 04:47

Researchers at The Wistar Institute, led by David B. Weiner, Ph.D., have unveiled a pioneering vaccination technology that integrates plasmid DNA with a lipid nanoparticle (LNP) delivery system. This innovative approach aims to enhance the efficacy and safety of vaccines by improving the way genetic material is delivered into cells.
The pre-clinical study demonstrates the potential of this next-generation technology to stimulate robust immune responses. By utilizing lipid nanoparticles, the researchers can effectively encapsulate plasmid DNA, ensuring its stability and facilitating its entry into target cells. This method not only increases the efficiency of vaccine delivery but also holds promise for a wide range of applications beyond infectious diseases, including cancer immunotherapy.
The findings represent a significant advancement in the field of genetic vaccination and could pave the way for more effective vaccines in the future. As the research progresses, the team hopes to further explore the technology's capabilities and its implications for public health.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...